This study is testing a new treatment for newly diagnosed glioblastoma (a type of brain cancer) after standard surgery and chemoradiation. It combines an investigational drug called 5-Aminolevulinic Acid (5-ALA) with a non-invasive ultrasound device (Low Intensity Diffuse Ultrasound Sonodynamic Therapy System, or LIDU SDT). The goal is to see if this combination, along with standard temozolomide chemotherapy, can improve how long patients live without their cancer growing (progression-free survival). You would be randomly assigned to receive either the active 5-ALA + LIDU SDT or a placebo and a sham (inactive) ultrasound. This study is for people aged 18 to 80 with a good general health status. The study status is currently unclear.

Study design

This is an interventional study planning to enroll 103 participants. Participants will be randomly assigned to one of two groups: active treatment or a placebo/sham group.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, progression-free survival, will be measured for up to 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.